Nanogen gets patent for enhancing molecular reactions:
This article was originally published in Clinica
Molecular and POC diagnostic products maker Nanogen has received a US patent relating to a technology that enables control over a wide range of molecular reactions involved in molecular analyses and diagnostics, including nucleic acid hybridisation and amplification, antibody and antigen reactions. The system described in the patent is at the core of Nanogen's electronic microarray technology, which uses electricity to move and concentrate biological samples in miniature formats for diagnostic applications. It greatly enhances the rate and specificity of the molecular biological reaction, said the San Diego, California firm.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.